These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36757117)

  • 41. Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension.
    Suzuki K; Otsuka N; Hizaki H; Hashimoto M; Kuwayama Y;
    Adv Ther; 2018 Jun; 35(6):796-808. PubMed ID: 29873009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.
    Akaishi T; Shimazaki A; Tonouchi A; Ueda K; Miyawaki N; Kawazu K
    J Ocul Pharmacol Ther; 2015 Nov; 31(9):518-24. PubMed ID: 26325164
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
    Erb C; Lanzl I; Seidova SF; Kimmich F
    Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of topical tafluprost on optic nerve head blood flow in patients with myopic disc type.
    Tsuda S; Yokoyama Y; Chiba N; Aizawa N; Shiga Y; Yasuda M; Yokokura S; Otomo T; Fuse N; Nakazawa T
    J Glaucoma; 2013; 22(5):398-403. PubMed ID: 23552835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spanish multicenter tafluprost tolerability study.
    Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
    Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients.
    Ranno S; Sacchi M; Brancato C; Gilardi D; Lembo A; Nucci P
    ScientificWorldJournal; 2012; 2012():804730. PubMed ID: 22606063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
    Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
    PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension.
    Lanzl I; Hamacher T; Rosbach K; Ramez MO; Rothe R; Růžičková E; Karhanová M; Kimmich F
    Clin Ophthalmol; 2013; 7():901-10. PubMed ID: 23717036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical comparison of the TonoVet(®) rebound tonometer and the Tono-Pen Vet(®) applanation tonometer in dogs and cats with ocular disease: glaucoma or corneal pathology.
    von Spiessen L; Karck J; Rohn K; Meyer-Lindenberg A
    Vet Ophthalmol; 2015 Jan; 18(1):20-7. PubMed ID: 24131625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
    Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
    Fukano Y; Kawazu K; Akaishi T; Bezwada P; Pellinen P
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.
    Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE
    Expert Opin Drug Saf; 2012 Jul; 11(4):519-25. PubMed ID: 22690824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the effect of hypertonic hydroxyethyl starch and mannitol on the intraocular pressure in healthy normotensive dogs and the effect of hypertonic hydroxyethyl starch on the intraocular pressure in dogs with primary glaucoma.
    Volopich S; Mosing M; Auer U; Nell B
    Vet Ophthalmol; 2006; 9(4):239-44. PubMed ID: 16771759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients.
    Holló G; Hommer A; Antón López A; Ropo A
    J Ocul Pharmacol Ther; 2014 Aug; 30(6):468-75. PubMed ID: 24738883
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study].
    Kuwayama Y; Komemushi S;
    Nippon Ganka Gakkai Zasshi; 2010 May; 114(5):436-43. PubMed ID: 20545217
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China.
    Sun X; Liu Q; Tang X; Yao K; Li Y; Yang J; Zhang M; Yuan H; Zheng Y; Li W; Peng H
    BMC Ophthalmol; 2022 Aug; 22(1):332. PubMed ID: 35932001
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study.
    Lee W; Lee S; Bae H; Kim CY; Seong GJ
    BMC Ophthalmol; 2017 Apr; 17(1):61. PubMed ID: 28454526
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
    Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY
    Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.